Shots:

• The CHMP positive opinion is based on P-III SELECT program including SELECT-NEXT- SELECT-BEYOND- SELECT-MONOTHERAPY- SELECT-COMPARE and SELECT-EARLY assessing Rinvoq in 4-400+ patients with mod. to sev. active RA
• In P-III studies- Rinvoq improved signs and symptoms of RA- inhibited radiographic progression and improved physical function- both as a monothx. and in combination with conventional synthetic DMARDs
• Rinvoq is a selective and reversible JAK inhibitor- currently under review with health authorities globally to treat mod. to sev. active RA and being evaluated in P-III studies for multiple immune-mediated inflammatory diseases

Click here to­ read full press release/ article | Ref: AbbVie | Image: AbbVie